Science 37 Holdings Inc
NASDAQ:SNCE
Intrinsic Value
Science 37 Holdings, Inc. is an emerging growth company, which provides technology-based solutions that enables decentralized clinical trials. [ Read More ]
The intrinsic value of one SNCE stock under the Base Case scenario is 15.52 USD. Compared to the current market price of 5.75 USD, Science 37 Holdings Inc is Undervalued by 63%.
Valuation Backtest
Science 37 Holdings Inc
Run backtest to discover the historical profit from buying and selling SNCE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Science 37 Holdings Inc
Current Assets | 75.5m |
Cash & Short-Term Investments | 56.4m |
Receivables | 10.6m |
Other Current Assets | 8.5m |
Non-Current Assets | 200k |
Other Non-Current Assets | 200k |
Current Liabilities | 18.1m |
Accounts Payable | 6.7m |
Accrued Liabilities | 8.4m |
Other Current Liabilities | 3m |
Non-Current Liabilities | 5.9m |
Other Non-Current Liabilities | 5.9m |
Earnings Waterfall
Science 37 Holdings Inc
Revenue
|
60.3m
USD
|
Cost of Revenue
|
-42.3m
USD
|
Gross Profit
|
17.9m
USD
|
Operating Expenses
|
-78.1m
USD
|
Operating Income
|
-60.2m
USD
|
Other Expenses
|
-64.4m
USD
|
Net Income
|
-124.7m
USD
|
Free Cash Flow Analysis
Science 37 Holdings Inc
What is Free Cash Flow?
SNCE Profitability Score
Profitability Due Diligence
Science 37 Holdings Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Science 37 Holdings Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
SNCE Solvency Score
Solvency Due Diligence
Science 37 Holdings Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Science 37 Holdings Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SNCE Price Targets Summary
Science 37 Holdings Inc
According to Wall Street analysts, the average 1-year price target for SNCE is 13.83 USD .
Ownership
SNCE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SNCE Price
Science 37 Holdings Inc
Average Annual Return | -23.28% |
Standard Deviation of Annual Returns | 63.78% |
Max Drawdown | -99% |
Market Capitalization | 34.7m USD |
Shares Outstanding | 6 028 170 |
Percentage of Shares Shorted | 0.41% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Science 37 Holdings, Inc. is an emerging growth company, which provides technology-based solutions that enables decentralized clinical trials. The company is headquartered in Culver City, California. The company went IPO on 2020-11-20. The firm develops Decentralized Clinical Trial Operating System (DCT OS), which enable workflow orchestration, evidence generation and data harmonization on a platform. Its platform configures studies and fused with its networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices. Its offerings include Fully DTC, Metasite, Technology+, Study Configuration and Diversity & Inclusion. Its technology and virtual capabilities ranging from executing a virtual clinical trial, to supplementing a trial as a virtual site, to enabling clinical trials through technology. The company’s customer base consists of pharmaceutical corporations, biotech companies, and academic and governmental institutions.
Contact
IPO
Employees
Officers
The intrinsic value of one SNCE stock under the Base Case scenario is 15.52 USD.
Compared to the current market price of 5.75 USD, Science 37 Holdings Inc is Undervalued by 63%.